"If you've ever worked with faculty, you'll know they have no interest in things they're not interested in!" he said. While AbbVie will retain the intellectual property rights for any of the drugs it developed that are studied under the deal, "if the university invents it, the university owns it," he said, adding that the school was "scrupulous about not compromising its publishing rate" and would not delay sharing its findings to benefit AbbVie.